BD
Therapeutic Areas
Dicerna Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Nedosiran (DCR-PHXC) | Primary Hyperoxaluria (Types 1, 2, 3) | Phase 3 |
| Belcesiran (DCR-A1AT) | Alpha-1 Antitrypsin Deficiency-associated Liver Disease | Phase 1/2 |
| DCR-AUD | Alcohol Use Disorder | Phase 1 |
| DCR-HBVS | Chronic Hepatitis B Virus Infection | Preclinical |
| DCR-MYC | Hepatocellular Carcinoma | Preclinical |
Leadership Team at Dicerna Pharmaceuticals
DM
Douglas M. Fambrough, Ph.D.
President and Chief Executive Officer
SA
Shreeram Aradhye, M.D.
EVP and Chief Medical Officer
JK
James K. Weiss, Ph.D.
EVP and Chief Business Officer
RT
R. Tyler Martin, M.D., J.D.
EVP, General Counsel, Corporate Secretary
MK
Matthew K. Fust
Chairman of the Board